{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:20:45Z","timestamp":1787815245995,"version":"build-2784847793"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Janus kinase inhibitors (JAKi) have demonstrated clinical utility in managing atopic dermatitis (AD), yet their broader potential across immune-mediated dermatoses remains inadequately explored, particularly within China\u2019s restrictive regulatory landscape for dermatologic indications. This review examines pathogenic mechanisms and emerging evidence supporting JAKi repositioning in seven dermatological conditions beyond AD: alopecia areata (AA), vitiligo, psoriasis, dermatomyositis (DM), pemphigus, bullous pemphigoid (BP), and chronic spontaneous urticaria (CSU)\u2014with emphasis on therapeutic gaps and opportunities specific to Chinese practice. We delineate disease-specific JAK-STAT dysregulation, including IFN-\u03b3-driven cytotoxicity in AA\/vitiligo, IL-23\/STAT3 activation in psoriasis, and type I interferon hyperactivation in DM. Key clinical findings from rigorous trials indicate that oral tofacitinib achieves PASI75 in 58% of psoriatic patients within 16 weeks and topical ruxolitinib induces facial repigmentation exceeding 75% in vitiligo. In contrast, while current evidence is substantially limited to isolated case reports, emerging data suggest that baricitinib may resolve steroid-refractory BP lesions within one month. Persistent limitations include reliance on small-scale studies for pemphigus and CSU, along with unresolved safety concerns regarding thrombosis risks in susceptible populations. Crucially, we identify therapeutic gaps in segmental vitiligo and juvenile DM where clinical data are absent. This synthesis advocates for randomized controlled trials to validate JAKi efficacy against biologics in high-burden diseases currently dependent on glucocorticoids.<\/jats:p>","DOI":"10.3389\/fmed.2026.1752145","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:08:56Z","timestamp":1787814536000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic expansion of JAK inhibitors in Chinese dermatological practice: beyond atopic dermatitis to novel autoimmune frontiers"],"prefix":"10.3389","volume":"13","author":[{"given":"Xinyan","family":"Lyu","sequence":"first","affiliation":[{"name":"Department of Dermatology, Shanghai Fifth People\u2019s Hospital of Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First People\u2019s Hospital of Kunshan","place":["Kunshan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First People\u2019s Hospital of Kunshan","place":["Kunshan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1110765","DOI":"10.3389\/fbioe.2023.1110765","article-title":"JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens","volume":"11","author":"Hu","year":"2023","journal-title":"Front Bioeng Biotechnol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1535-7163.MCT-22-0323","article-title":"JAK: not just another kinase","volume":"21","author":"Agashe","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1111\/jcmm.17168","article-title":"JAK\/STAT: why choose a classical or an alternative pathway when you can have both?","volume":"26","author":"Puigdevall","year":"2022","journal-title":"J Cell Mol Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41375-025-02569-8","article-title":"Malignant JAK-signaling: at the interface of inflammation and malignant transformation","volume":"39","author":"Perner","year":"2025","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"106362","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharmacol Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3390\/cancers13040800","article-title":"Janus kinases in leukemia","volume":"13","author":"Raivola","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41590-024-01805-0","article-title":"Baseline JAK-STAT signaling maintains immune cell homeostasis","volume":"25","author":"Bock","year":"2024","journal-title":"Nat Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"906763","DOI":"10.3389\/fphar.2022.906763","article-title":"One of the active ingredients in Paeoniae Radix Alba functions as JAK1 inhibitor in rheumatoid arthritis","volume":"13","author":"Xiao","year":"2022","journal-title":"Front Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1291106","DOI":"10.1080\/2162402X.2017.1291106","article-title":"JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer","volume":"6","author":"Lu","year":"2017","journal-title":"Oncoimmunology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3389\/fimmu.2018.01510","article-title":"Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system","volume":"9","author":"Kubo","year":"2018","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"142365","DOI":"10.1016\/j.scitotenv.2020.142365","article-title":"Perfluorooctanesulfonate and perfluorooctanoate exacerbate airway inflammation in asthmatic mice and in vitro","volume":"766","author":"Yang","year":"2021","journal-title":"Sci Total Environ"},{"key":"B14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/1759720X18776224","article-title":"The role of the JAK\/STAT signal pathway in rheumatoid arthritis","volume":"10","author":"Malemud","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S2468-1253(23)00208-X","article-title":"Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study","volume":"8","author":"Vermeire","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.1172\/JCI141772","article-title":"Baricitinib restrains the immune dysregulation in patients with severe COVID-19","volume":"130","author":"Bronte","year":"2020","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2411834","DOI":"10.1080\/09546634.2024.2411834","article-title":"Longer-term safety and efficacy of baricitinib for atopic dermatitis in pediatric patients 2 to <18 years old: a randomized clinical trial of extended treatment to 3.6 years","volume":"35","author":"Wollenberg","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.jaad.2017.12.019","article-title":"Emerging therapies for atopic dermatitis: JAK inhibitors","volume":"78","author":"Cotter","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jdv.14695","article-title":"Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials","volume":"32","author":"Kuo","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jaut.2017.06.006","article-title":"Small molecules to the rescue: inhibition of cytokine signaling in immune-mediated diseases","volume":"85","author":"Gadina","year":"2017","journal-title":"J Autoimmun"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1001\/jama.2024.15568","article-title":"Chronic spontaneous urticaria: a review","volume":"332","author":"Kolkhir","year":"2024","journal-title":"Jama"},{"key":"B26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia areata: an update on etiopathogenesis, diagnosis, and management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1056\/NEJMicm2033425","article-title":"Dermatomyositis","volume":"384","author":"O'Connell","year":"2021","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(05)66829-8","article-title":"Pemphigus","volume":"366","author":"Bystryn","year":"2005","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41572-025-00595-5","article-title":"Bullous pemphigoid","volume":"11","author":"Akbarialiabad","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B31","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e12555","DOI":"10.1111\/dth.12555","article-title":"Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors","volume":"30","author":"Wcis\u0142o-Dziadecka","year":"2017","journal-title":"Dermatol Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1203475420972340","article-title":"Cutaneous JAK expression in vitiligo","volume":"25","author":"Abdel Motaleb","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"B35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/ijms19010171","article-title":"Psoriasis: a STAT3-centric view","volume":"19","author":"Calautti","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri3581","article-title":"Regulation of type I interferon responses","volume":"14","author":"Ivashkiv","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/brain\/awy105","article-title":"JAK Inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis","volume":"141","author":"Ladislau","year":"2018","journal-title":"Brain J Neurol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e12696","DOI":"10.1111\/dth.12696","article-title":"Tofacitinib as the potent treatment for refractory pemphigus: a possible alternative treatment for pemphigus","volume":"31","author":"Tavakolpour","year":"2018","journal-title":"Dermatol Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s10020-018-0025-6","article-title":"OSMR gene effect on the pathogenesis of chronic autoimmune urticaria via the JAK\/STAT3 pathway","volume":"24","author":"Luo","year":"2018","journal-title":"Mol Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"6716419","DOI":"10.1155\/2017\/6716419","article-title":"Expression of the JAK\/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis","volume":"2017","author":"Juczynska","year":"2017","journal-title":"Mediat Inflamm"},{"key":"B41","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/jamadermatol.2025.0982","article-title":"Ivarmacitinib for moderate to severe atopic dermatitis in adults and adolescents: a phase 3 randomized clinical trial","volume":"161","author":"Zhao","year":"2025","journal-title":"JAMA Dermatol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jaad.2025.10.005","article-title":"Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: results from the 52-week open-label extension period of the phase 2 STRIDE study","volume":"94","author":"Papp","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/bjd\/ljaf482","article-title":"Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II\/III clinical trial","volume":"194","author":"Wang","year":"2026","journal-title":"Br J Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/ard-2024-226385","article-title":"Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial","volume":"84","author":"Liu","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.2147\/DDDT.S172638","article-title":"Role of Janus kinase inhibitors in the treatment of alopecia areata","volume":"12","author":"Triyangkulsri","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/bjd.16808","article-title":"Alopecia areata: a review of disease pathogenesis","volume":"179","author":"Rajabi","year":"2018","journal-title":"Br J Dermatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/1878-0261.12135","article-title":"Inhibition of IL-6-JAK\/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1\/NKG2D ligand levels","volume":"12","author":"Xu","year":"2018","journal-title":"Mol Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41375-017-0004-x","article-title":"Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer\/T-cell lymphoma","volume":"32","author":"Nairism\u00e4gi","year":"2018","journal-title":"Leukemia"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI insight"},{"key":"B50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jaad.2018.02.031","article-title":"Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis","volume":"78","author":"Putterman","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/1203475417716363","article-title":"A case of topical ruxolitinib treatment failure in alopecia areata","volume":"21","author":"Deeb","year":"2017","journal-title":"J Cutan Med Surg"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI insight"},{"key":"B54","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40257-024-00846-3","article-title":"Integrated safety analysis of ritlecitinib, an oral JAK3\/TEC family kinase inhibitor, for the treatment of alopecia areata from the ALLEGRO clinical trial program","volume":"25","author":"King","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"eaam7710","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci Transl Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/bjd.14416","article-title":"Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo","volume":"174","author":"Wang","year":"2016","journal-title":"Br J Dermatol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/jid.2014.529","article-title":"Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo","volume":"135","author":"Agarwal","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/1744666X.2025.2510491","article-title":"Meta-analysis for alterations of IFN-\u03b3, TNF-\u03b1 and granzyme B levels in vitiligo patients","volume":"21","author":"Giri","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.coi.2016.09.008","article-title":"Understanding mechanisms of autoimmunity through translational research in vitiligo","volume":"43","author":"Strassner","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"B61","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"102655","DOI":"10.1016\/j.eclinm.2024.102655","article-title":"Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"73","author":"Passeron","year":"2024","journal-title":"eClinicalMed"},{"key":"B63","doi-asserted-by":"publisher","first-page":"7488","DOI":"10.3390\/ijms21207488","article-title":"New treatment addressing the pathogenesis of psoriasis","volume":"21","author":"Tokuyama","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","first-page":"eads3530","DOI":"10.1126\/sciadv.ads3530","article-title":"T(H)17 cells regulate chemokine expression in epithelial cells through C\/EBP\u03b2 and dictate host sensitivity to colitis and cancer immunity","volume":"11","author":"Xing","year":"2025","journal-title":"Sci Adv"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1038\/s41467-018-04974-3","article-title":"Act1 is a negative regulator in T and B cells via direct inhibition of STAT3","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat Commun"},{"key":"B66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41419-019-2212-y","article-title":"Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation","volume":"11","author":"Thatikonda","year":"2020","journal-title":"Cell Death Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"8900","DOI":"10.3390\/ijms23168900","article-title":"IL11 stimulates IL33 expression and proinflammatory fibroblast activation across tissues","volume":"23","author":"Widjaja","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B68","doi-asserted-by":"publisher","first-page":"6061","DOI":"10.3390\/ijms24076061","article-title":"Assessment of the potential role of selected single nucleotide polymorphisms (SNPs) of genes related to the functioning of regulatory T cells in the pathogenesis of psoriasis","volume":"24","author":"Purzycka-Bohdan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B69","doi-asserted-by":"publisher","first-page":"712781","DOI":"10.3389\/fimmu.2021.712781","article-title":"The antimicrobial peptide human \u03b2-defensin-3 accelerates wound healing by promoting angiogenesis, cell migration, and proliferation through the FGFR\/JAK2\/STAT3 signaling pathway","volume":"12","author":"Takahashi","year":"2021","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"117932","DOI":"10.1016\/j.bmc.2024.117932","article-title":"Design of a potent and selective dual JAK1\/TYK2 inhibitor","volume":"114","author":"Mammoliti","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"B71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"B73","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/BOR.0000000000000540","article-title":"Dermatomyositis etiopathogenesis: a rebel soldier in the muscle","volume":"30","author":"Pinal-Fernandez","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"155633","DOI":"10.1016\/j.cyto.2021.155633","article-title":"Abnormalities of the type I interferon signaling pathway in lupus autoimmunity","volume":"146","author":"Gallucci","year":"2021","journal-title":"Cytokine"},{"key":"B77","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","article-title":"TYK2: an emerging therapeutic target in rheumatic disease","volume":"20","author":"Morand","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"115906","DOI":"10.1016\/j.carbpol.2020.115906","article-title":"Receptor and signaling pathway involved in bovine lymphocyte activation by atractylodis macrocephalae polysaccharides","volume":"234","author":"Xu","year":"2020","journal-title":"Carbohydr Polym"},{"key":"B80","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2020-218690","article-title":"Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis","volume":"80","author":"Kim","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B84","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.jaad.2021.07.003","article-title":"Tofacitinib as treatment for refractory dermatomyositis: a retrospective study from 2 academic medical centers","volume":"86","author":"Min","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3899\/jrheum.220367","article-title":"A retrospective analysis of outcome in melanoma differentiation-associated gene 5-related interstitial lung disease treated with tofacitinib or tacrolimus","volume":"49","author":"Fan","year":"2022","journal-title":"J Rheumatol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: current and future therapeutic strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e716","DOI":"10.1097\/MJT.0000000000001251","article-title":"Imiquimod-associated pemphigus foliaceus","volume":"29","author":"Farid","year":"2022","journal-title":"Am J Ther"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1563286","DOI":"10.3389\/fimmu.2025.1563286","article-title":"JAK-STAT pathway, type I\/II cytokines, and new potential therapeutic strategy for autoimmune bullous diseases: update on pemphigus vulgaris and bullous pemphigoid","volume":"16","author":"Lin","year":"2025","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1220887","DOI":"10.3389\/fimmu.2023.1220887","article-title":"Janus kinase inhibitors in autoimmune bullous diseases","volume":"14","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"155835","DOI":"10.1016\/j.cyto.2022.155835","article-title":"Moxibustion regulates the polarization of macrophages through the IL-4\/STAT6 pathway in rheumatoid arthritis","volume":"152","author":"Zhong","year":"2022","journal-title":"Cytokine"},{"key":"B91","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s10875-011-9597-4","article-title":"Cognate Th2-B cell interaction is essential for the autoantibody production in pemphigus vulgaris","volume":"32","author":"Zhu","year":"2012","journal-title":"J Clin Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e70121","DOI":"10.1111\/exd.70121","article-title":"JAK1\/2 inhibitors alleviate the damage of intercellular adhesion by reducing endoplasmic reticulum stress-induced apoptosis in pemphigus vulgaris","volume":"34","author":"Chen","year":"2025","journal-title":"Exp Dermatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1001\/jamaophthalmol.2018.3789","article-title":"Treatment of mucous membrane pemphigoid with Janus kinase inhibitor baricitinib","volume":"136","author":"Sarny","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.ajoc.2021.101104","article-title":"Tofacitinib for refractory ocular mucous membrane pemphigoid","volume":"22","author":"James","year":"2021","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B95","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5070\/D327754365","article-title":"Significant improvement of dermatitis herpetiformis with tofacitinib","volume":"27","author":"Kahn","year":"2021","journal-title":"Dermatol Online J"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1001\/jamadermatol.2021.3174","article-title":"Epidermolysis bullosa pruriginosa treated with baricitinib","volume":"157","author":"Jiang","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/ced.14998","article-title":"Successful use of tofacitinib in epidermolysis bullosa pruriginosa","volume":"47","author":"Chen","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1111\/ijd.17464","article-title":"Upadacitinib leading to resolution of refractory mucosal erosions in a case of pemphigus vulgaris","volume":"64","author":"Hren","year":"2025","journal-title":"Int J Dermatol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/exd.13446","article-title":"Structural proteins of the dermal-epidermal junction targeted by autoantibodies in pemphigoid diseases","volume":"26","author":"Goletz","year":"2017","journal-title":"Exp Dermatol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/ijms24010323","article-title":"Expression of the selected proteins of JAK\/STAT signaling pathway in diseases with oral mucosa involvement","volume":"24","author":"Ociepa","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1111\/ajd.14389","article-title":"Expression of JAK\/STAT signalling in bullous pemphigoid","volume":"66","author":"Iyengar","year":"2025","journal-title":"Australas J Dermatol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e15754","DOI":"10.1111\/dth.15754","article-title":"Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor baricitinib","volume":"35","author":"Xiao","year":"2022","journal-title":"Dermatol Ther"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1464474","DOI":"10.3389\/fimmu.2024.1464474","article-title":"Treatment and molecular analysis of bullous pemphigoid with tofacitinib: a case report and review of current literature","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/all.13950","article-title":"Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study","volume":"75","author":"Simon","year":"2020","journal-title":"Allergy"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1080\/09546634.2022.2089331","article-title":"Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review","volume":"33","author":"Husein-ElAhmed","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1007\/s12325-024-02810-3","article-title":"Study design of a phase 2\/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT","volume":"41","author":"Murrell","year":"2024","journal-title":"Adv Ther"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1279139","DOI":"10.3389\/fimmu.2023.1279139","article-title":"Key genes and immune infiltration in chronic spontaneous urticaria: a study of bioinformatics and systems biology","volume":"14","author":"Su","year":"2023","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","article-title":"Urticaria","volume":"8","author":"Kolkhir","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B110","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/cbf.3481","article-title":"Role of IL-9 and IL-10 in the pathogenesis of chronic spontaneous urticaria through the JAK\/STAT signalling pathway","volume":"38","author":"Feng","year":"2020","journal-title":"Cell Biochem Funct"},{"key":"B111","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.anai.2025.10.020","article-title":"Efficacy and safety of povorcitinib in adults with chronic spontaneous urticaria: phase 2 results.","volume":"135","author":"Metz","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1466058","DOI":"10.3389\/fimmu.2024.1466058","article-title":"Case report: exploration of abrocitinib in the treatment of refractory chronic spontaneous urticaria: a case series","volume":"15","author":"Du","year":"2024","journal-title":"Front Immunol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.revmed.2025.06.003","article-title":"Safety profile of JAK inhibitors in inflammatory or autoimmune diseases","volume":"46","author":"Moreau","year":"2025","journal-title":"La Revue de Medecine Interne"},{"key":"B114","doi-asserted-by":"publisher","first-page":"106359","DOI":"10.1016\/j.phrs.2022.106359","article-title":"Cardiovascular safety, cancer and Jak-inhibitors: differences to be highlighted","volume":"183","author":"Benucci","year":"2022","journal-title":"Pharmacol Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"13181","DOI":"10.3390\/ijms241713181","article-title":"Effects of tofacitinib on muscle remodeling in experimental rheumatoid sarcopenia","volume":"24","author":"Bermejo-\u00c1lvarez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B116","doi-asserted-by":"publisher","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1111\/ijd.17973","article-title":"308\u2009nm Excimer laser combined with JAK inhibitors for adult localized non-segmental vitiligo: a multicenter randomized controlled trial","volume":"64","author":"Qi","year":"2025","journal-title":"Int J Dermatol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1021\/acs.jmedchem.2c01800","article-title":"Development and therapeutic implications of tyrosine kinase 2 inhibitors","volume":"66","author":"Zhang","year":"2023","journal-title":"J Med Chem"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1093\/ibd\/izab135","article-title":"Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise","volume":"27","author":"Danese","year":"2021","journal-title":"Inflamm Bowel Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1752145\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:08:58Z","timestamp":1787814538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1752145\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":119,"alternative-id":["10.3389\/fmed.2026.1752145"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1752145","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1752145"}}